Want to see AU:BIT full AI Analyst Report?
Biotron (BIT) AI Stock Analysis
Biotron
(ASX:BIT)
Biotron scores at the low end of the range, driven primarily by very weak financial fundamentals: revenue has fallen to zero, operating cash burn of roughly A$1.78 million re-accelerated in the latest year, and the company remains reliant on equity raises with attendant dilution risk. The main offsets are a debt-free balance sheet, equity rebuilt to about A$2.92 million and roughly two years of cash runway at the current burn rate, plus demonstrated cost discipline that narrowed losses versus prior peaks. Valuation offers no support with a negative P/E and no dividend, while the absence of technical indicators and the sub-penny, high-beta share price add further uncertainty. This is a high-risk, binary story whose value depends on clinical outcomes rather than current financial performance. Earnings call and corporate event components were excluded due to missing data, with their weight redistributed proportionally.
Biotron (BIT) vs. iShares MSCI Australia ETF (EWA)
Not enough price history over this period.
- Market Cap
- AUD 1.36M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -3.6
- Beta (1Y)
- 1.04
- Revenue Growth
- ―
- EPS Growth
- -100.00%
- Country
- Australia
- Employees
- 4
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Biotron Business Overview & Revenue Model
Company Description
Biotron Limited is an Australian biotechnology firm dedicated to the creation and market introduction of small molecule therapies designed to combat a range of viral illnesses. Its flagship antiviral compound, BIT225, is currently undergoing Phase II...
How the Company Makes Money
null
Biotron Financial Statement Overview
Summary
Biotron is a pre-commercial, clinical-stage biotech with no product revenue. The income statement scores very poorly (11/100) as revenue fell to zero from roughly A$1.81 million, leaving the company entirely dependent on external funding with no visible path to breakeven, despite a narrower net loss of about A$1.52 million versus A$3.44 million a year earlier. Cash flow is equally weak (13/100), with operating and free cash flow of about -A$1.78 million, a sharp re-acceleration in burn from -A$0.57 million the prior year, confirming losses are genuine cash costs. The balance sheet is the one relative bright spot (45/100): zero debt, equity rebuilt to roughly A$2.92 million and total assets of about A$3.74 million, implying roughly two years of runway. However, the asset base is tiny, has previously dipped into negative equity, and further equity raises and shareholder dilution appear likely.
Income Statement
11Very NegativeBalance Sheet
45NeutralCash Flow
13Very Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -868 | 0 | 1.81M | 1.65M | 1.43M | 1.56M |
| Gross Profit | -1,651 | -1,913 | 1.81M | 1.65M | 1.39M | 1.51M |
| EBITDA | -1.92M | -1.93M | -327.65K | -5.04M | -4.88M | -2.73M |
| Net Income | -1.94M | -1.52M | -318.57K | -3.44M | -3.49M | -2.78M |
Balance Sheet | ||||||
| Total Assets | 3.86M | 3.74M | 980.40K | 493.48K | 4.14M | 1.91M |
| Cash, Cash Equivalents and Short-Term Investments | 1.64M | 1.55M | 931.68K | 393.20K | 3.98M | 1.74M |
| Total Debt | 0 | 0 | 0 | 7,130 | 45.27K | 77.24K |
| Total Liabilities | 1.16M | 817.93K | 428.51K | 737.51K | 962.49K | 813.57K |
| Stockholders Equity | 2.70M | 2.92M | 551.89K | -244.03K | 3.17M | 1.09M |
Cash Flow | ||||||
| Free Cash Flow | -1.92M | -1.78M | -568.87K | -3.57M | -3.29M | -2.44M |
| Operating Cash Flow | -1.92M | -1.78M | -565.80K | -3.57M | -3.29M | -2.44M |
| Investing Cash Flow | 111.51K | 111.51K | -3,071 | 0 | 0 | 0 |
| Financing Cash Flow | 2.58M | 2.29M | 1.11M | -22.62K | 5.53M | -33.17K |
Biotron Peers Comparison
Overall Rating
AU:BIO71Outperform
AU:IMC53Neutral
AU:RCE46Neutral
AU:BGT43Neutral
AU:SPL40Underperform- AU:BIT27Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:BIO | 71Outperform | AUD 83.31M | 22.36 | 46.74% | ― | 29.68% | 1520.00% |
| AU:IMC | 53Neutral | AUD 12.91M | -3.10 | -31.88% | ― | 5.85% | 45.13% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:RCE | 46Neutral | AUD 110.10M | -6.95 | 84.67% | ― | ― | 42.51% |
| AU:BGT | 43Neutral | AUD 6.13M | -1.87 | -143.11% | ― | ― | 38.52% |
| AU:SPL | 40Underperform | AUD 217.31M | -26.32 | -42.35% | ― | 145.32% | 25.75% |
| AU:BIT | 27Underperform | AUD 5.57M | -3.56 | -54.03% | ― | ― | -100.00% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:BIT | Biotron Limited | ― | ― | ― | |
| AU:SPL | Starpharma Holdings Limited | 0.45 | 0.11 | 32.35% | |
| AU:IMC | Immuron Limited | 0.04 | -0.04 | -49.37% | |
| AU:BGT | Bio-Gene Technology Ltd. | 0.01 | -0.01 | -50.00% | |
| AU:BIO | Biome Australia Ltd | 0.36 | -0.09 | -20.00% | |
| AU:RCE | Recce Pharmaceuticals Ltd. | 0.36 | -0.04 | -10.00% |
Biotron Corporate Events
Biotron Files Updated ASX Corporate Governance Appendix 4G for FY 2026
Biotron Limited has lodged its Appendix 4G and updated corporate governance statement for the year ended 30 June 2026, confirming that the statement is available on its website and has been approved by the board as at 27 August 2026. The filing outli...
Biotron Outlines Governance and Diversity Framework for FY2026
Biotron has detailed its corporate governance framework for the year to 30 June 2026, confirming broad alignment with the ASX Corporate Governance Principles and Recommendations. The board retains responsibility for strategy, financial oversight, ris...
Biotron Posts Wider Annual Loss but Boosts Asset Backing Amid Material Uncertainty
Biotron Limited, an ASX-listed Australian biotechnology company, focuses on antiviral drug development for infectious diseases with a research-led approach. Its activities are concentrated in the life sciences sector, where clinical milestones and fu...
Biotron Advances Hepatitis B Candidate BIT-HBV001 Toward Human Trials After Strong Preclinical Data
Biotron has reported new preclinical data from The Scripps Research Institute showing that its lead candidate BIT-HBV001 exhibits strong antiviral activity against both Hepatitis B Virus and Hepatitis Delta Virus in cell-based studies. The compound e...
Biotron Updates Market on Directors’ Shareholding Changes
Biotron Limited has notified the ASX of changes in the shareholdings of directors Paul Kasian and Graeme Wald, in accordance with listing rule 3.19A. The disclosure reinforces the company’s commitment to regulatory compliance and transparent re...
Biotron Seeks ASX Quotation for 83 Million New Shares
Biotron Limited has applied for quotation on the ASX of 83,333,333 new ordinary fully paid shares, expanding its listed securities base under the ticker BIT. The newly issued shares, dated 13 July 2026, arise from the exercise or conversion of existi...
Biotron Clears First SedRx Milestone After EMA Feedback on Regulatory Pathway
Biotron has met the first milestone under its Sedarex acquisition after securing formal feedback from the European Medicines Agency on the regulatory pathway for SedRx. The EMA guidance gives the company a clearer roadmap for designing pivotal clinic...
Biotron Lists Additional Ordinary Shares Following Option Conversions
Biotron Limited has applied for quotation on the ASX of 5,720 new ordinary fully paid shares, to be listed under its existing ticker BIT. The securities arise from the exercise or conversion of existing options or other convertible instruments, resul...
Biotron Secures R&D Tax Rebate to Support Antiviral Drug Development
Biotron Limited has received an R&D Tax Incentive rebate of $525,869 from the Australian Government for the 2024/25 financial year, reflecting 43.5% of its eligible research and development expenditure. The rebate, derived from its antiviral drug...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 30, 2026